Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
暂无分享，去创建一个
A. Italiano | S. Domchek | Young-Ae Park | B. Kaufman | Z. Lai | M. Krebs | S. Postel-Vinay | Ding Wang | H. Angell | J. Delord | S. Im | S. Waqar | J. Alexandre | B. You | M. Lanasa | S. Bastian | P. Herbolsheimer | L. Opincar | C. Gresty